| Literature DB >> 34306095 |
Yijia Zhou1, Yuandong Liao1, Chunyu Zhang1, Junxiu Liu1, Wei Wang1, Jiaming Huang1, Qiqiao Du1, Tianyu Liu1, Qiaojian Zou1, Hua Huang1, Pan Liu2, Shiyin Ooi1, Run Chen1, Meng Xia1, Hongye Jiang1, Manman Xu1, Yuwen Pan1, Shuzhong Yao1.
Abstract
Cancer stem cells are a key population participating in the promotion of the cervical cancer progression through interacting with cancer cells. Existing studies have preliminary revealed that cervical cancer stem cells contribute to tumor recurrence and chemotherapy resistance. However, the specific mechanisms involved in regulating cell functions remain largely unknown. Here, we analyzed published data from public databases and our global transcriptome data, thus identifying cancer-related signaling pathways and molecules. According to our findings, upregulated TAB2 was correlated to stem cell-like properties of cervical cancer. Immunohistochemistry staining of TAB2 in normal and cervical cancer tissues was performed. The cell function experiments demonstrated that knockdown of TAB2 reduced the stemness of cervical cancer cells and, importantly, prevented cervical cancer progression. Collectively, the therapeutic scheme targeting TAB2 may provide an option for overcoming tumor relapse and chemoresistance of cervical cancer via obstructing stemness maintenance.Entities:
Year: 2021 PMID: 34306095 PMCID: PMC8266450 DOI: 10.1155/2021/6550388
Source DB: PubMed Journal: Stem Cells Int Impact factor: 5.443
Figure 1The ability of cell stemness maintenance in Siha sphere is significantly higher than that in parental cells. (a) The sphere formation ability was significantly enhanced in the Siha sphere group compared with the Siha group. (b) The enrichment of tumor stem cells significantly enhanced sphere formation efficiency in the Siha sphere group compared with the Siha group. (c) Western blot was performed to detect protein levels of SOX2 and BMI1 in Siha cells and Siha sphere.
Figure 2The next-generation sequencing and bioinformation analysis. (a) The DEGs were displayed by volcano scatter plots. (b) The KEGG enrichment analysis of DEGs. (c) GSEA showing the related pathway regulated by TAB2. (d) The Human Protein Atlas dataset presenting the expression of TAB2 in normal and cervical cancer tissues. (e) Kaplan-Meier analysis of overall survival in patients with cervical cancer (n = 292). Patients were divided into low and high group according to the cut-off level of TAB2 in TCGA database. (f) Coexpression analysis of TAB2 and SOX2 based on the data from StarBase. (g) Coexpression analysis between TAB2 and BMI1 according to the data from StarBase.
Figure 3The expression of TAB2 in cervical cancer. (a) IHC staining showing that positive expressions of TAB2 and SOX2 were significantly high in cervical cancer. (b) The mRNA expression of TAB2 in cervical cancer cell lines was tested by qPCR experiment. (c) The protein level of TAB2 in different cervical cancer cell lines.
Figure 4TAB2 knockdown inhibits the stemness of cervical cancer cells. (a) Protein levels of SOX2 and BMI1 were detected by Western blot after knockdown of TAB2 in Siha cells. (b) Protein levels of SOX2 and BMI1 were detected by Western blot after knockdown of TAB2 in MS751 cells. (c) TAB2 knockdown inhibited the sphere formation efficiency in Siha and MS751 cells. (d) TAB2 knockdown inhibited the capacity of sphere formation in Siha cells. (e) TAB2 knockdown inhibited the capacity of sphere formation in MS751 cells. (f) ALDEFLUOR kit was used to assess the proportion of ALDHbr in Siha cells intervened with TAB2 or not. (g) The ability of stemness maintenance in MS751 cells was assessed by ALDEFLUOR kit.
Figure 5TAB2 knockdown inhibits the biological functions of CC cells. (a) Colony numbers in Siha cells transfected with siTAB2-1, siTAB2-2, or siNC detected by colony formation assay. (b) Colony numbers in MS751 cells transfected with siTAB2-1, siTAB2-2, or siNC detected by colony formation assay. (c) Cell viability of Siha cells transfected with siTAB2-1, siTAB2-2, or siNC detected by CCK-8 assay. (d) Cell cycle distribution of Siha cells transfected with siTAB2-1, siTAB2-2, or siNC detected by the Cell Cycle Kit. (e) Cell viability of MS751 cells transfected with siTAB2-1, siTAB2-2, or siNC detected by CCK-8 assay. (f) Cell cycle distribution of MS751 cells transfected with siTAB2-1, siTAB2-2, or siNC detected by the Cell Cycle Kit. (g) Migration in Siha cells transfected with siTAB2-1, siTAB2-2, or siNC detected by Transwell assay. (h) Migration in MS751 cells transfected with siTAB2-1, siTAB2-2, or siNC detected by Transwell assay. (i) The apoptotic rate of Siha cells transfected with siTAB2-1, siTAB2-2, or siNC detected by flow cytometry. (j) The apoptotic rate of MS751 cells transfected with siTAB2-1, siTAB2-2, or siNC detected by flow cytometry.